Literature DB >> 7517677

Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.

U D McCann1, A Ridenour, Y Shaham, G A Ricaurte.   

Abstract

(+/-)3,4-Methylenedioxymethamphetamine (MDMA; "Ecstasy"), an increasingly popular recreational drug, is known to damage brain serotonin 5-hydroxytryptamine (5-HT) neurons in experimental animals. Whether MDMA is neurotoxic in humans has not been established. Thirty MDMA users and 28 controls were admitted to a controlled inpatient setting for measurement of biologic and behavioral indexes of central 5-HT function. Outcome measures obtained after at least 2 weeks of drug abstinence included concentrations of monoamine metabolites in cerebrospinal fluid (CSF), prolactin responses to L-tryptophan, nociceptive responses to ischemic pain, and personality characteristics in which 5-HT has been implicated (i.e., impulsivity and aggression). Subjects with a history of MDMA exposure had lower levels of CSF 5-hydroxyindoleacetic acid (the major metabolite of 5-HT) than controls (p = .001). Although they resembled controls in their prolactin response to L-tryptophan and their response to ischemic pain, MDMA users had lower scores on personality measures of impulsivity (p = .004) and indirect hostility (p = .009). The CSF findings suggest that 5-HT neurotoxicity may be a potential complication of MDMA use. Further, differences in personality support the view that 5-HT systems are involved in modulating impulsive and aggressive personality traits. Additional studies of MDMA-exposed individuals are needed to confirm and extend the present findings. Such studies could help elucidate the role of 5-HT in normal brain function as well as in neuropsychiatric disease states.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517677     DOI: 10.1038/npp.1994.15

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  70 in total

Review 1.  Ten years of 'ecstasy'.

Authors:  C M Milroy
Journal:  J R Soc Med       Date:  1999-02       Impact factor: 5.344

2.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

3.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

4.  The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).

Authors:  A C Parrott; J Rodgers; T Buchanan; A B Scholey; T Heffernan; J Ling
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

5.  In vitro metabolism of 3,4-methylenedioxymethamphetamine in human hepatocytes.

Authors:  Corinne Ramaley; Susan C Leonard; Jeffrey D Miller; Denita Takesha-Mashia Wilson; Sai Y Chang; Qingyu Chen; Feng Li; Chengan Du
Journal:  J Anal Toxicol       Date:  2014-03-28       Impact factor: 3.367

6.  The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe; Phillip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

7.  The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.

Authors:  Jonathan P Roiser; Robert D Rogers; Lynnette J Cook; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-08-29       Impact factor: 4.530

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

10.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.